Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methyl Salicylate→

Methyl Salicylate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
119-36-8
Molecular formula
C8H8O3
Molecular weight
152.1473 g/mol
Drug class
Topical counterirritantsalicylate ester used in external analgesic products
Mechanism of action
Applied topically, methyl salicylate produces local counterirritant and warming effects. It is absorbed through skin and hydrolysed to salicylate, which can inhibit cyclo-oxygenase and prostaglandin synthesis; systemic exposure can occur with excessive application or occlusion.
Indications / reported uses
  • Temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains in authorised topical external-analgesic formulations

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · NLM MeSH — Methyl salicylate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methyl Salicylate Environmental Risk Assessment (ERA) (the Methyl Salicylate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.